全文获取类型
收费全文 | 20335篇 |
免费 | 1661篇 |
国内免费 | 654篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 216篇 |
妇产科学 | 140篇 |
基础医学 | 833篇 |
口腔科学 | 139篇 |
临床医学 | 1483篇 |
内科学 | 2514篇 |
皮肤病学 | 276篇 |
神经病学 | 1872篇 |
特种医学 | 199篇 |
外国民族医学 | 1篇 |
外科学 | 743篇 |
综合类 | 2232篇 |
一般理论 | 3篇 |
预防医学 | 1150篇 |
眼科学 | 153篇 |
药学 | 8717篇 |
6篇 | |
中国医学 | 1259篇 |
肿瘤学 | 675篇 |
出版年
2024年 | 38篇 |
2023年 | 316篇 |
2022年 | 404篇 |
2021年 | 685篇 |
2020年 | 666篇 |
2019年 | 756篇 |
2018年 | 763篇 |
2017年 | 825篇 |
2016年 | 723篇 |
2015年 | 719篇 |
2014年 | 1449篇 |
2013年 | 2212篇 |
2012年 | 1311篇 |
2011年 | 1379篇 |
2010年 | 1103篇 |
2009年 | 908篇 |
2008年 | 857篇 |
2007年 | 884篇 |
2006年 | 731篇 |
2005年 | 657篇 |
2004年 | 546篇 |
2003年 | 533篇 |
2002年 | 379篇 |
2001年 | 366篇 |
2000年 | 282篇 |
1999年 | 241篇 |
1998年 | 223篇 |
1997年 | 215篇 |
1996年 | 212篇 |
1995年 | 188篇 |
1994年 | 158篇 |
1993年 | 188篇 |
1992年 | 182篇 |
1991年 | 137篇 |
1990年 | 131篇 |
1989年 | 106篇 |
1988年 | 117篇 |
1987年 | 75篇 |
1986年 | 87篇 |
1985年 | 127篇 |
1984年 | 113篇 |
1983年 | 82篇 |
1982年 | 92篇 |
1981年 | 61篇 |
1980年 | 70篇 |
1979年 | 55篇 |
1978年 | 63篇 |
1977年 | 56篇 |
1976年 | 47篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
41.
M. Bergström G. Westerberg G. Németh M. Traut G. Gross G. Greger H. Müller-Peltzer A. Safer S.-Å. Eckernäs A. Grahnér B. Långström 《European journal of clinical pharmacology》1997,52(2):121-128
Objective: The aim of the study was to investigate whether or not esuprone binds substantially to MAO-A in the human brain. Methods: In a randomised double-blind placebo-controlled study 16 male healthy volunteers were examined␣with positron emission tomography
(PET) with [11C]harmine. Eight of the volunteers were given daily doses of 800 mg esuprone, four were given bi-daily doses of 300 mg moclobemide,
and four volunteers were given placebo tablets. PET was performed before initiation of a 7-day treatment period. On day 7,
one investigation was made immediately before administration of the drug, representing 23 h after the previous day's treatment
for esuprone and 11 h after the last tablets of moclobemide. Further investigations were made 4 h and 8 h after the morning
dose on day 7. Results: PET showed a high degree of binding of [11C]harmine, a high-affinity ligand for MAO-A, before the start of treatment, and a marked and similar reduction after treatment
with esuprone and moclobemide. A slight tendency for normalisation of enzyme binding was observed at the last time point.
In the placebo group no change was observed. Plasma kinetics of esuprone showed a rapid elimination with a half-life of about
4 h. Conclusion: The study demonstrates that esuprone was comparable to moclobemide in its effect on MAO-A inhibition in the brain at the
doses given. This is an illustration of the potential of PET to monitor drug effects directly on target biochemical systems
in the brain in human volunteers, and the possibility of using these data, rather than pharmacokinetic data, for the determination
of dosing intervals.
Received: 21 August 1996 / Accepted in revised form: 22 November 1996 相似文献
42.
In the 12-day-old rat cochlea, the synthesis of inositol phosphates (IPs) can be activated via M3 cholinoceptors. This stimulation is blocked by ototoxins (mercury, ethacrynate, cisplatin, neomycin), drugs with side effects that lead to damage of hair cells and strial cells. As these toxic effects can be reversed in vivo by thiol molecules, we investigated whether modifications of thiol compounds could be involved in ototoxin-induced inhibition of the IP turnover in the cochlea. For this purpose, we assessed whether the sulphhydryl-modifying reagents N -ethylmaleimide and cadmium modify the carbachol-stimulated formation of IPs in the 12-day-old rat cochlea. Both molecules inhibit the carbachol effect on a dose-dependent way without altering the basal metabolism of IPs. As cadmium may block some calcium channels, the effect of verapamil, another calcium channel antagonist, was tested. Verapamil (1 –50 μM) does not alter carbachol-evoked IP formation, suggesting that the inhibitory effect of cadmium is not due to a calcium influx block. Binding experiments with the muscarinic ligand quinuclidinyl benzylate (QNB) showed that the sulphhydryl-modifying reagents do not displace QNB from binding sites. Combining ototoxins and reagents shows that N -ethylmaleimide acts synergistically with all ototoxins but ethacrynate while cadmium does so only with mercury. Both N -ethylmaleimide and cadmium have additive effects with ethacrynate. As a supplement, disulphide bond-modifying agents do not alter the carbachol-enhanced metabolism of IPs. These results suggest that molecules having thiol-modifying properties inhibit the carbachol-induced turnover of IPs without acting at the muscarinic sites. Since thiol modifiers and ethacrynate share similar features in both QNB binding and IP response it is hypothesized that they strike common targets, possibly G proteins. 相似文献
43.
Rolf W. Hartmann Martin Frotscher Dorothea Ledergerber Gerald A. Wchter Gertrud L. Grün Tom F. Sergejew 《Archiv der Pharmazie》1996,329(5):251-261
In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing a OCH3 substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituent in 2-position were synthesized with and without C1-spacer between the rings (compounds 2 – 26 ). The compounds were tested in vitro for inhibition of the three target enzymes P450 arom (human placental microsomes), P450 17 (rat testicular microsomes), and P450 TxA2 (citrated human whole blood). To examine selectivity, some compounds were further tested in vitro for inhibition of P450 18 (bovine adrenal mitochondria), P450 see (bovine adrenal mitochondria) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compounds were examined in Sprague Dawley rats regarding P450 TxA2 inhibition, reduction of plasma testosterone concentration, antiuterotrophic activity (inhibition of the uterotrophic activity of androstenedione), reduction of plasma estradiol concentration (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compounds, which represent a novelty in the field of azole inhibitors of steroidogenic P450 enzymes, strong inhibitors of P450 arom and/or P450 17 were found: 7-OCH3-2-(imidazol-4-ylmethylene)-1-tetralone ( 4 ) and 7-OCH3-2-(imidazol-4-ylmethyl)-tetralin ( 12 ) are among the most potent inhibitors of P450 arom in vitro known so far. Compound 4 is a selective inhibitor, whereas 12 shows in addition strong inhibition of P450 17. In contrast to 12 , the 6-OCH3 derivative (compound 11 ) is a selective inhibitor of P450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compounds show a marked inhibition of P450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone ( 13 ) is a selective inhibitor of P450 TxA2, whereas 7-OCH3-2-(imidazol-1-ylmethyl)-tetralin ( 17 ) as well as 2-(imidazol-1-ylmethyl)-tetralin ( 16 ) and 7-OCH3-2-imidazol-1-yl-3,4-dihydronaphthalene ( 25 ) additionally show strong inhibition of P450 arom and P450 17. Regarding the other steroidogenic P450 enzymes as well as corticosterone formation, the compounds show only little inhibitory activity. Aldosterone formation, however, is inhibited at low concentrations. Nevertheless, 4 and 12 are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P450 arom fadrozole. The compounds show activity in the aforementioned in vivo tests. 相似文献
44.
L. Niskanen H. Enlund V. Jormanainen A. Nissinen M. Uusitupa 《European journal of clinical pharmacology》1994,46(2):101-105
The utilisation of antidiabetic drugs reflects both the prevalence of diabetes and the different therapeutic traditions of physicians. A questionnaire survey to study attitudes to the use of oral antidiabetic drugs amongst physicians and possible changes in treatment habits was carried out in a representative sample of Finnish physicians (n=454) in 1992 and the results were compared with those of a similar survey carried out in 1985, and with drug utilisation statistics.The mean fasting blood glucose level at which a physician would start pharmacological treatment was 8.7 mmol·l–1, which was significantly lower than in the 1985 survey. The responses to various case histories suggested a more active approach to pharmacological treatment compared to the 1985 survey. Insulin treatment especially seems to have gained in popularity. This change in attitude was paralled by an increase in the consumption of antidiabetic drugs in Finland during the observation period. The increase in use of oral drugs was steeper in Finland than in Norway and Sweden.Whether this active approach will improve the metabolic control and prognosis of patients with Type 2 diabetes, remains to be demonstrated. 相似文献
45.
B. A. Reikhardt L. M. Belyavtseva O. G. Kulikova 《Bulletin of experimental biology and medicine》1992,113(5):682-684
Academician S. V. Anichkov Department of Pharmacology, Research Institute of Experimental Medicine, Academy of Medical Sciences, St. Petersburg. (Presented by Academician of the Academy of Medical Sciences A. N. Klimov.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 113, No. 5, pp. 506–508, May, 1992. 相似文献
46.
[目的 ]观察解毒保肾汤治疗早期糖尿病性肾病的疗效 .[方法 ]将诊断为早期糖尿病性肾病的病人随机分为 2组 ,其中治疗组 4 4例给予解毒保肾汤 ,对照组 2 0例给予阳性对照药络汀新 ,观察治疗前后 2组病人的临床症状、空腹血糖、糖化血红蛋白量及尿蛋白排泄率等的变化 .[结果 ]治疗组总有效率为 80 % ,对照组总有效率为 6 5 % ,治疗组疗效优于对照组 ;治疗组在改善临床症状 ,降低空腹血糖、糖化血红蛋白量及尿蛋白排泄率等方面均优于对照组 .[结论 ]解毒保肾汤能够降低早期糖尿病性肾病患者的血糖、减少尿蛋白的排泄 ,具有一定的保护肾脏功能 ,对早期糖尿病性肾病有治疗作用 . 相似文献
47.
朱雪梅 《浙江中医药大学学报》2007,31(5):630-631
乌梅中医临床内服外用均有奇效,但常被杏、山杏、山李、桃、陈乌梅、诃子等伪劣品所混淆,从来源鉴别、性状鉴别、显微鉴别、理化鉴别四方面可将它们相互鉴别区分开来。 相似文献
48.
49.
微乳对难溶性药物增溶机理的研究 总被引:17,自引:1,他引:16
目的:初步探讨微乳对难溶性药物的增溶机理.方法:经处方筛选及相图研究确定(BL-9/正丁醇3∶1)/油/水比例为9∶1∶40的微乳处方;以二氢吡啶类药物为模型药物,测定其在微乳、胶束和油相中的溶解度及油/水分配系数;根据化学结构,采用计算机软件计算药物的特性参数,并结合模型药物的特性分析微乳增溶难溶性药物的机理.结果:微乳对药物的增溶效果远大于油相和胶束,并随药物的脂溶性和空间结构的改变而变化.结论:微乳可用于增溶难溶性药物,且脂溶性越大,空间位阻越小,增溶效果越明显. 相似文献
50.
本文重点介绍近年来糖尿病患者调脂治疗,主要包括临床常用的他汀类、贝特类、烟酸等药物降胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)水平、升高高密度脂蛋白-胆固醇(HDL-C),以及减少心血管事件的疗效、不良反应等。 相似文献